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The Arenaviridae family, together with the Bunyaviridae and Orthomyxoviridae
families, is one of the three negative-stranded RNA viral families that encode an
endonuclease in their genome. The endonuclease domain is at the N-terminus of
the L protein, a multifunctional protein that includes the RNA-dependent RNA
polymerase. The synthesis of mRNA in arenaviruses is a process that is primed
by capped nucleotides that are ‘stolen’ from the cellular mRNA by the
endonuclease domain in cooperation with other domains of the L protein. This
molecular mechanism has been demonstrated previously for the endonuclease
of the prototype Lymphocytic choriomeningitis virus (LCMV). However, the
mode of action of this enzyme is not fully understood as the original structure
did not contain catalytic metal ions. The pivotal role played by the cap-snatching
process in the life cycle of the virus and the highly conserved nature of the
endonuclease domain make it a target of choice for the development of novel
antiviral therapies. Here, the binding affinities of two diketo-acid (DKA)
compounds (DPBA and L-742,001) for the endonuclease domain of LCMV
were evaluated using biophysical methods. X-ray structures of the LCMV
endonuclease domain with catalytic ions in complex with these two compounds
were determined, and their efficacies were assessed in an in vitro endonuclease-
activity assay. Based on these data and computational simulation, two new
DKAs were synthesized. The LCMV endonuclease domain exhibits a good
affinity for these DKAs, making them a good starting point for the design of
arenavirus endonuclease inhibitors. In addition to providing the first example of
an X-ray structure of an arenavirus endonuclease incorporating a ligand, this
study provides a proof of concept that the design of optimized inhibitors against
the arenavirus endonuclease is possible.
1. Introduction
The Arenaviridae is a family of viruses that are associated with
rodent-transmitted infections in humans. These viruses cause
chronic and asymptomatic infections in rodents, and constitute
a reservoir of human pathogens across the world (Buchmeier
et al., 2007). Indeed, several arenaviruses, including Lassa
virus, Lujo virus, Guanarito virus, Sabia´ virus, Chapare virus,
Machupo virus and Junı´n virus, are responsible for outbreaks
of haemorrhagic fever and constitute a major public health
concern (Bowen et al., 1997; Enria et al., 2008; Briese et al.,
2009). In West Africa alone (Sierra Leone, Guinea, Liberia,
Nigeria and Benin), Lassa virus is responsible for several
hundred thousand infections per year (Gu¨nther & Lenz,
2004). It is a common endemic infection that in most cases
leads to hearing loss, tremors and encephalitis, and in 1% of
cases becomes a deadly haemorrhagic fever (Yun et al., 2015).
The last Lassa fever outbreak, in Nigeria between August 2015
and May 2016, had a case-fatality rate (CFR) of 53.9% based
on confirmed WHO data of 165 cases and 89 deaths
(confirmed through laboratory testing; World Health Orga-
nization, 2016). Lymphocytic choriomeningitis virus (LCMV)
was the first arenavirus to be isolated and is considered to be
the prototype virus for the family. Responsible for occasional
transmission to man, it may result in life-threatening menin-
gitis and/or haemorrhagic fever, and several clinical studies
have suggested that its pathogenicity has been underestimated
(Mets et al., 2000; Schulte et al., 2006; Jamieson et al., 2006;
Bonthius, 2012). Because its natural host is the common house
mouse (Mus musculus), it has a global distribution, with
LCMV infections reported in Europe, the Americas, Australia
and Japan. LCMV is a human pathogen of significant clinical
relevance, causing central nervous system disease, congenital
malformation, choriomeningitis, and systemic and highly fatal
infection in immunocompromised organ-transplant recipient
patients (Fisher-Hoch et al., 1995; Mets et al., 2000; Barton et
al., 2002; Fischer et al., 2006; Schulte et al., 2006; MacNeil et al.,
2012). Humans are generally infected by arenaviruses through
exposure to aerosols of fresh urine, droppings, saliva or
nesting materials from infected rodents or during organ
transplantation (Fischer et al., 2006). Despite the widespread
threat to human health that these pathogens represent, there
are no vaccines and only limited therapeutic options (Lee et
al., 2011). The only licensed drug for the treatment of human
arenavirus infection is the broad-spectrum antiviral ribavirin,
which is only partially effective and is associated with signifi-
cant toxicity (McCormick et al., 1986; Kilgore et al., 1997;
Enria et al., 2008). Therefore, there is an unmet need to
identify novel compounds that could be developed into anti-
viral drugs to combat human-pathogenic arenaviruses.
Arenaviruses are enveloped viruses with a bi-segmented
negative single-stranded RNA genome. Each segment
encodes two proteins separated by an intergenic region (IGR)
in an ambisense manner. The L RNA segment encodes the
large protein L (200 kDa) and the small disordered protein
Z (11 kDa) (Buchmeier et al., 2007). L (UniProt P14240) is a
multi-domain protein: its N-terminus includes an endo-
nuclease domain (residues 1–196) followed by a viral RNA-
dependent RNA polymerase (RdRp) domain, but it lacks a
capping machinery (Lo´pez et al., 2001). The Z protein, which
contains a RING finger motif, is a multifunction protein that
regulates the life cycle of the virus and, during budding,
assembles to form the matrix (Cornu & de la Torre, 2001;
Perez et al., 2003, 2004; Hastie, Zandonatti et al., 2016). The S
RNA segment encodes the precursor of the mature virion
glycoprotein GP-C (75 kDa), which after post-translational
cleavage gives GP-1 (40–46 kDa) and GP-2 (35 kDa) (Hastie,
Igonet et al., 2016), and the nucleoprotein NP (63 kDa;
Buchmeier et al., 2007). NP forms a polymer that protects the
genomic (and antigenomic) RNA (RNAv). L and NP together
with RNAv form an active ribonucleic complex for replication
and transcription (Pinschewer et al., 2003). Arenaviruses
belongs to the negative RNA viruses; therefore, the first step
in the viral cycle starts by the transcription of L and NP viral
messenger RNAs (mRNAs; Perez & de la Torre, 2003). This
step is undertaken by the L protein and starts (possibly with
the help of NP) by recruiting cellular mRNA as a first step.
The L protein cleaves and snatches the native cellular mRNA
cap structure through its endonuclease domain after 11
nucleotides, and uses it as a primer sequence for the RdRp
domain of the L protein to synthesize the viral mRNA. The
crystal structure of the LCMV endonuclease domain (ENDO)
was originally determined some time ago (Morin et al., 2010),
but in this original structure the catalytic ions necessary to
fully understand the mode of action of the endonuclease were
missing. Cap-snatching is essential to the life cycle of the virus,
and this makes the endonuclease domain a target of choice for
drug-design development (Charrel et al., 2011). This
mechanism is shared by Orthomyxoviridae and Bunyaviridae,
two families that harbour prominent pathogenic members and
the endonucleases of which have been used in drug develop-
ment (Reguera et al., 2010; Kowalinski et al., 2012; DuBois et
al., 2012). However, Arenaviridae endonuclease is a challen-
ging target for inhibitor development. Indeed, it has the most
phylogenetically remote structure compared with the enzymes
from Orthomyxoviridae and Bunyaviridae (Ferron et al.,
2017). Previous structural studies of Lassa virus endonuclease
characterized the complex with catalytic ions (Wallat et al.,
2014), but failed to obtain a complex with an inhibitor
(Reguera et al., 2016). Nevertheless, there is great interest in
viral endonuclease inhibitors that are optimally designed to
occupy the active site and chelate the metal ions (Rogolino et
al., 2012).
In this study, we selected two molecules that are known to
target the influenza virus endonuclease (Orthomyxoviridae) as
a starting point for the structure-based drug design of anti-
arenavirus compounds (Noble et al., 2012; Stevaert et al.,
2013). We characterized the binding affinity of DPBA (1) and
L-742,001 (2) (Fig. 1a) for the LCMV ENDO by biophysical
methods. We evaluated their efficacy in an in vitro endo-
nuclease assay and solved crystal structures of LCMV ENDO
with catalytic ions (Mg2+ or Mn2+) and each of these two
diketo acids (DKAs). Based on the structure analysis and in
silico analysis, we synthesized two new DKAs, compounds (3)
and (4) (Fig. 1b), which exhibited not only a better affinity for
LCMV ENDO but also a better inhibition of its activity.
2. Materials and methods
2.1. Sequence analysis
All available full-length sequences of Arenaviridae L
proteins were downloaded from NCBI. Using the redundancy
option in Jalview, all identical sequences were removed. The
working set was composed of 384 sequences, including
Mammarenavirus and Reptiarenavirus sequences. This subset
was aligned with MUSCLE (Edgar, 2004) using the balanced
option optimized for long sequences and large data sets.
The first 220 amino acids corresponding to an extended
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endonuclease domain were selected. The working set was
again purged of identical sequences, leaving 245 sequences.
The resulting alignment was analysed to specifically target
identical residues and the information was correlated with the
LCMV endonuclease structure. The motif conservation was
represented with WebLogo (Crooks et al., 2004). A list of the
sequences used is summarized in Supplementary Table S1 and
an alignment performed with ESPript (Gouet et al., 2003) is
shown in Supplementary Fig. S1.
2.2. Protein expression and purification
Wild-type ENDO (ENDO-WT) and its D118A and D88A
mutants were cloned into pDEST14 with an N-terminal
hexahistidine tag and expressed in Escherichia coli
Rosetta (DE3) pLysS cells at 17C in TB medium overnight
after induction with 500 mM IPTG. Cell pellets from
harvested cultures were resuspended in 50 mM Tris buffer pH
8.0, 300 mM NaCl, 10 mM imidazole, 0.1% Triton X-100, 5%
glycerol. Lysozyme (0.25 mg ml1), DNase I (10 mg ml1) and
EDTA-free protease-inhibitor cocktail (Roche) were added
before sonication. Immobilized metal-ion chromatography of
the clarified lysates was performed on a 5 ml HisPrep column
(A¨KTAxpress FPLC system, GE Healthcare) eluted using the
same buffer with 500 mM imidazole. The eluted His-tagged
fraction was diluted and purified on a HiTrap Q Sepharose
1 ml column (GE Healthcare). Proteins were eluted using a
linear gradient from 50 mM to 1 M NaCl in 10 mM HEPES
buffer pH 7.5, 2 mM DTT. Size-exclusion chromatography
was performed on a preparative Superdex 200 column (GE
Healthcare) pre-equilibrated with 10 mM HEPES pH 8.0,
50 mM NaCl, 2 mM DTT. The protein was concentrated to
25 mg ml1 and frozen in liquid nitrogen.
2.3. Compounds and substrate characterization
2.3.1. Differential scanning fluorimetry (DSF). Melting-
temperature (Tm) values of the proteins were determined by a
thermofluorescence-based assay. In 96-well thin-walled PCR
plates, 11 ml protein solution (ENDO) was added to 11 ml of
compound (1) or compound (2) and/or metal ions (Mg2+ or
Mn2+) in 10 mM HEPES buffer pH 8.0, 50 mM NaCl, 2 mM
DTT. Finally, 3 ml of the fluorescent dye SYPRO Orange was
added (715-fold diluted in H2O; Molecular Probes). The
thermal denaturation of the proteins was followed by
measuring the fluorescence emission at 575 nm (with excita-
tion at 490 nm) using a CFX Connect Real-Time PCR
Detection System (Bio-Rad). The final concentrations were
adjusted to 75 mM protein, 0.5 mM MgCl2, 0.5 mM MnCl2,
450 mM compound (1) or (2) (final ligand:protein ratio = 6)
and 5% DMSO. The denaturation midpoints of the proteins
were calculated with the Boltzmann equation using GraphPad
Prism. All measurements were performed in triplicate.
2.3.2. Microscale thermophoresis (MST). MST experiments
were performed on a Monolith NT.115 instrument (Nano-
Temper Technologies). Proteins were labelled with the red
fluorescent dye NT-647 using the Protein Labeling Kit RED-
NHS (NanoTemper Technologies). The concentration of the
labelled protein was kept constant at 100 nM, while the
concentration of the compound was varied. A 15-step twofold
dilution series beginning at 500, 250 or 125 mM finally yielded
16 different concentrations of the tested compound [(1)–(4)].
Experiments were carried out in 10 mM
HEPES buffer pH 8 containing 100 mM
NaCl, 1 mM DTT, 0.05%(w/v) Tween
20, 0.25 mM MgCl2 and 0.25 mM
MnCl2. The final samples were adjusted
to 5% DMSO to ensure the solubility
of the compounds. The samples
were centrifuged for 5 min at
13 000 rev min1 to remove potential
aggregates and the supernatant was
loaded into standard treated MST-grade
glass capillaries (NanoTemper Technol-
ogies). After a 5 min incubation period
the MST was measured with 80% LED
power and 80% infra-red laser power.
Kd values were determined using the
NanoTemper analysis software.
2.3.3. Isothermal titration calori-
metry (ITC). Purified ENDO was
diluted in ITC buffer consisting of
10 mM HEPES pH 8.0, 50 mM NaCl,
2 mM DTT, 0.25 mM MgCl2, 0.25 mM
MnCl2. Compound (1) was diluted in
the same buffer. The final DMSO
concentration was 5% in the cell and in
the syringe. Titrations were carried out
research papers
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Figure 1
Structures of 2,4-dioxo-4-phenylbutanoic acid [DPBA, (1)], (Z)-4-{1-benzyl-4-[(4-chlorophenyl)-
methyl]piperidin-4-yl}-2-hydroxy-4-oxobut-2-enoic acid [L-742,001, (2)], 2-hydroxy-4-(biphenyl-4-
yl)-4-oxobut-2-enoic acid (3) and 2-hydroxy-4-oxo-4-(phenanthren-3-yl)but-2-enoic acid (4).
in a MicroCal ITC200 microcalorimeter (GE Healthcare).
Experiments were designed with a titrant concentration
[1 mM DPBA (1) in the syringe] ten times the analyte
concentration (100 mM protein in the cell), using 19 injections
at 25C. A first small injection (0.2 ml) was included in the
titration protocol in order to remove air bubbles trapped in
the syringe prior to titration. Raw data were scaled after
setting the zero to the titration saturation heat value.
Integrated raw ITC data were fitted to a one-site nonlinear
least-squares fit model using the MicroCal Origin plugin as
implemented in Origin 9.1 (OriginLab). Each experiment was
performed three times and the data are presented as the mean
 standard deviation.
2.3.4. In vitro endonuclease assay. An in vitro endo-
nuclease assay was performed to investigate the inhibition of
compounds (1) and (2). The reaction was carried out in 20 ml
samples consisting of 20 mM Tris–HCl pH 8, 150 mM NaCl,
1 mM TCEP, 2 mM MnCl2. ENDO-WT (20 mM) was premixed
with 50, 125, 250, 500, 1000 or 2000 mM of each compound and
the reaction was started by adding 1 mM of a 19-nucleotide
single-stranded RNA (Morin et al., 2010). The reaction
mixtures were incubated at 25C and the reaction was stopped
after 6 h by adding 20 ml loading buffer (formamide containing
10 mM EDTA). For experiments to compare the inhibition of
DPBA (1) and compounds (3) and (4), ENDO-WT (20 mM)
was premixed with 50 mM of each compound and the same
protocol as above was applied. The reaction products were
analyzed on 20% polyacrylamide/8 M urea gels. The un-
digested RNAs were visualized on photostimulated plates
using a Fluorescent Image Analyzer FLA3000 (Fuji) and
quantified using Image Gauge (Fuji). Graphs were plotted
using GraphPad Prism. All experiments were performed in
triplicate.
2.4. Crystallization, data collection and structure
determination
2.4.1. Crystallization. All crystals were grown at 20C using
the sitting-drop vapour-diffusion method in 96-well plates
(Greiner) by mixing 200 nl protein solution (13 mg ml1 in
10 mM HEPES pH 8.0, 50 mM NaCl, 2 mM DTT) with 100 nl
reservoir solution using a Mosquito robot (TTP Labtech).
Crystals of ENDO-WT complexed with ions grew in a reser-
voir solution consisting of 100 mM sodium citrate pH 6.2, 3%
isopropanol using protein solution supplemented with 1 mM
MgCl2. Crystals of ENDO-WT complexed with ions and
DPBA (1) grew in a reservoir solution consisting of 100 mM
sodium citrate pH 6.2, 3.5% isopropanol using protein solu-
tion supplemented with 1 mM MgCl2 and 2 mM DPBA (1)
(solubilized in PEG 400). Crystals of ENDO-WT complexed
with ions and L-742,001 (2) grew in a reservoir solution
consisting of 100 mM sodium citrate pH 6, 3.5% 2-propanol
using protein solution supplemented with 1 mM MnCl2 and
2 mM L-742,001 (2) (solubilized in PEG 400). Crystals of the
ENDO-D118A mutant grew in a reservoir solution consisting
of 100 mM sodium citrate pH 6.3, 8% 2-propanol. All crystals
were cryocooled in liquid N2 using 20%(v/v) glycerol in
mother liquor as a cryoprotectant.
2.4.2. Data collection and structure determination of
LCMV. The data for ENDO-WT complexed with ions were
collected on beamline ID23-1 and the data for ENDO-WT
complexed with L-742,001 (2) were collected on beamline
ID23-2 at the European Synchrotron Radiation Facility
(ESRF). The data for ENDO-WT complexed with DPBA (1)
and the ENDO-D118A mutant were collected on the
PROXIMA-1 beamline at Synchrotron SOLEIL. Data were
processed, analysed and scaled using the autoPROC toolbox
(Vonrhein et al., 2011). Phases were obtained by molecular
replacement using Phaser (McCoy et al., 2007) with PDB entry
3jsb (Morin et al., 2010) as a search model. All water and
ligand molecules were removed from the search structure.
Rebuilding of the initial model using AutoBuild (Terwilliger et
al., 2008) was then performed. Subsequently, all-atom
isotropic temperature-factor refinement cycles were
performed with phenix.refine (Afonine et al., 2012) and/or with
BUSTER (Blanc et al., 2004). Electron-density maps were
inspected using Coot (Emsley et al., 2010). Extra density
accounting for ions and/or compounds was observed for the
complexed structures, but none was found for the mutant
structures (Supplementary Fig. S4b). The structures were
evaluated using MolProbity (Chen et al., 2010) and
PROCHECK (Laskowski et al., 1993). Structural analysis was
performed and high-resolution figures were produced with
UCSF Chimera (Pettersen et al., 2004). Data-collection and
refinement statistics are given in Table 1.
2.5. Molecular docking
For the molecular docking, we used the crystal structures
of ENDO-WT complexes with different ions. The three-
dimensional structure of ENDO-WTwas energy-minimized by
the steepest-gradient method of energy minimization followed
by conjugate-gradient minimization, using the MMTK and
Amber packages (Cornell et al., 1995; Hinsen, 2000; Lindorff-
Larsen et al., 2010). Compounds were designed using BKChem
v.0.13.0 (Kosata & Danne, 2010) and geometry-restrained
using eLBOW (Moriarty et al., 2009). The Mol2 and PDB file
formats of the ligands and receptor were converted to PDBQT
format using UCSF Chimera prior to docking. All of the water
and solvent atoms of the protein were removed and the polar
hydrogens and polar charge were added to the ions and ligand
prior to docking. The protein was kept rigid while the ligand
was allowed to rotate and explore more flexible binding
pockets. The docking of the ligands onto ENDO-WT was
performed iteratively using AutoDock Vina v.1.1.2 (Trott &
Olson, 2010). The best poses from the first round of docking
were used as seeds for the second round. The grid box size was
initially 40  40  40 in order to verify that our ligands will
preferentially bind in the catalytic site. The grid box size was
further optimized to 23.2  15.6  21.2, thus covering the
binding pockets; the default scoring function was used for
docking.
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Binding modes of the docked complexes were obtained and
sorted based on their binding energy; ions and amino-acid
residues that were present at a distance less of 3 A˚ were
considered to be binding partners of the ligands. The binding
modes were compared with these of the native structure.
Figures showing the interactions of the docked complexes
were generated using UCSF Chimera (Pettersen et al., 2004).
2.6. Chemicals and chemistry
2,4-Dioxo-4-phenylbutanoic acid [DPBA, (1)] was purchased
from Interchim. (Z)-4-[1-Benzyl-4-[(4-chlorophenyl)methyl]-
piperidin-4-yl]-2-hydroxy-4-oxobut-2-enoic acid [L-742,001,
(2)] was synthesized as previously reported (Stevaert et al.,
2015). 2-Hydroxy-4-(biphenyl-4-yl)-4-oxobut-2-enoic acid (3)
and 2-hydroxy-4-oxo-4-(phenanthren-3-yl)but-2-enoic acid
(4) were synthesized as described in the literature (Patil et al.,
2007; Bhatt et al., 2011) and the conditions used for their
preparation are detailed in Appendix A.
3. Results and discussion
The endonuclease catalytic reaction is driven by two-metal-ion
catalysis (TMIC): (i) to form a stable intermediate and then
(ii) to break the phosphodiester backbone of the nucleic acid
chain (Palermo et al., 2015). Indeed, as shown by Steitz &
Steitz (1993), the TMIC reaction is driven by two divalent
metal ions positioned on each side of the targeted scissile
phosphate bond to be cleaved. The metal ions facilitate an
SN2-type reaction, in which one metal ion favours the
formation of the nucleophilic O atom from a water molecule
and the other helps the exit of the leaving group by associating
with a nonbridging phosphoryl O atom. The catalytic centre of
the ENDO resides in the N-terminal part around Asp88 and
should contain two Mg2+ (or Mn2+) ions, which are critical for
the RNA-cleavage mechanism. Our strategy to design inhi-
bitors of this activity is to develop compounds that are able to
block and inhibit the catalytic centre through the trapping of
critical metal ions, resulting in functional impairment.
DPBA (1) and L-742,001 (2) are DKAs that carry a
chelating motif consisting of a -ketone, an enolizable
-ketone and a carboxylic acid that is able to chelate the
divalent metal ions that are present in the active sites of some
enzymes (Kowalinski et al., 2012; DuBois et al., 2012; Fig. 1).
These compounds have been identified as potent inhibitors of
the activity of influenza PA Nter in enzymatic assays or cell
cultures and mouse models (Reguera et al., 2010; Carcelli et al.,
2014; Stevaert et al., 2015). This prompted us to investigate
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Table 1
Data-collection and refinement statistics for the LCMV endonuclease domain complexed with ions and compounds and for its D118A mutant.
Values in parentheses are for the highest resolution shell.
LCMV ENDO complexed
with Mg2+ ions
LCMV ENDO complexed
with DPBA (1)
LCMV ENDO complexed
with L-742,001 (2)
LCMV ENDO-
D118A mutant
PDB code 5ltf 5ltn 5t2t 5lts
Beamline ID23-1, ESRF PROXIMA-1, SOLEIL ID23-2, ESRF PROXIMA-1, SOLEIL
Wavelength (A˚) 0.976 0.978 0.873 0.978
Resolution range (A˚) 48.46–2.43 (2.52–2.43) 53.59–1.88 (1.95–1.88) 54.06–1.97 (2.04–1.97) 53.57–2.51 (2.60–2.51)
Space group P41 P41 P41 C2221
a, b, c (A˚) 108.4, 108.4, 54.1 107.2, 107.2, 53.8 108.1, 108.1, 54.1 144.8, 159.2, 52.7
, ,  () 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90
Molecules in asymmetric unit 2 2 2 2
Total reflections 67793 (6444) 241187 (14092) 308124 (31957) 73597 (7143)
Unique reflections 23573 (2252) 49896 (4927) 44686 (4457) 21183 (2063)
Multiplicity 2.9 (2.9) 4.8 (2.9) 6.9 (7.2) 3.5 (3.4)
Completeness (%) 96.0 (96.0) 99.6 (99.5) 100 (100) 99.0 (100)
Mean I/(I) 13.61 (1.58) 8.54 (1.20) 12.51 (2.02) 14.17 (2.09)
Wilson B factor (A˚2) 57.12 37.53 33.03 58.27
Rmerge 0.046 (0.607) 0.094 (0.868) 0.094 (0.870) 0.060 (0.594)
Rmeas 0.056 (0.744) 0.105 (1.15) 0.102 (0.938) 0.071 (0.704)
CC1/2 0.999 (0.586) 0.996 (0.416) 0.998 (0.715) 0.997 (0.649)
No. of reflections used in refinement 22999 49844 44682 21091
No. of free reflections 1932 2457 2210 1004
Rwork 0.18 (0.27) 0.19 (0.29) 0.18 (0.27) 0.20 (0.27)
Rfree 0.23 (0.33) 0.21 (0.29) 0.22 (0.30) 0.22 (0.29)
No. of atoms in structure
Total 3240 3353 3586 3184
Macromolecules 3080 3064 3193 3063
Ligands 2 60 47 8
R.m.s.d., bonds (A˚) 0.009 0.010 0.008 0.013
R.m.s.d., angles () 1.09 1.10 1.86 1.67
Ramachandran plot
Favoured (%) 92 97 97 97
Allowed (%) 5.7 1.9 2.3 2.7
Outliers† (%) 2.3 1.1 0.7 0.3
Average B factor (A˚2) 75.92 50.30 41.98 74.32
† Outliers are in highly flexible regions of the protein.
whether they can also have a similar effect on LCMV ENDO,
which is a homologue of influenza PA Nter.
3.1. Biophysical characterization of the effect of DKA
compounds on ENDO
3.1.1. Thermal stability by DSF. In order to characterize the
effect of the DKAs (1) and (2) on the endonuclease domain,
we first investigated the thermal stability of ENDO-WT and its
D88A and D118A mutants (ENDO-D88A and ENDO-
D118A, respectively). The two ENDO mutations (D88A and
D118A) were selected to elucidate the roles of the two
aspartates in metal and ligand binding. D88A is a mutation of
the key residue supposedly involved in bivalent metal-ion
coordination, while D118A is a mutation of a conserved
residue distant from the active site in the vicinity of the
catalytic pocket (Morin et al., 2010). To determine the thermal
stability of ENDO-WT and its mutants, we used a thermo-
fluorescence-based assay. In this assay, the fluorescence of a
hydrophobic dye is measured as it binds to hydrophobic
regions of the protein that are solvent-exposed as the protein
is denatured by heating. The melting temperature (Tm) of the
protein is then determined from a temperature-dependent
fluorescence curve. As shown in Fig. 2(a), the changes in the
Tm of ENDO-WT and the ENDO-D118A mutant are similar,
in contrast to those for the ENDO-D88A mutant.
In the absence of ions the Tm for both ENDO-WT and
ENDO-D118A is around 40C, whereas that for ENDO-
D88A is 10C higher, indicating that the enzyme is more
stable. The addition of divalent ions (Mg2+, Mn2+ or a mixture
of both) increases the Tm by 5C for both ENDO-WT and
ENDO-D118A. On the other hand, ENDO-D88A presents no
significant increase in Tm under similar conditions. These
results show the following. (i) ENDO-WT and ENDO-D118A
are stabilized by divalent ions, but ENDO-D88A is not. (ii)
Asp118 makes no direct or indirect interactions with the ions
and has virtually no influence on the
stability of the protein. This result was
confirmed by our structural study (see
x3.2). (iii) ENDO-D88A is not affected
by either the presence or the absence of
divalent ions, indicating that Asp88 is
involved in divalent ion binding.
We next assessed the effect of di-
valent metal ions and ligand binding on
ENDO-WT and its mutants (Fig. 2a).
For both ENDO-WT and ENDO-
D118A, the addition of either DPBA
(1) or L-742,001 (2) in the presence of
metal ions led to a significant positive
Tm shift of greater than 10
C, which
confirmed the high affinity of these
ligands for the enzyme. No effect was
observed when using ENDO-D88A.
This latter result provides evidence that
in absence of divalent ions the enzyme
displays no affinity for the compounds.
The increase in Tm indicates a gain in
stability owing to the binding effect of
the compounds to ENDO complexed
with divalent ions. As no gain of stabi-
lity was observed with the D88A
mutant, a mutation that abrogates metal
ion binding, we infer that the binding of
ligands (1) and (2) is performed through
metal-ion chelation.
3.1.2. Binding affinity by MST and
ITC. To further characterize the ligand-
binding mode, we used microscale
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Figure 2
(a) Thermal stability of ENDO proteins determined by differential scanning fluorimetry (DSF). The
melting temperatures (Tm) of ENDO-WT, ENDO-D118A and ENDO-D88A (75 mM; P) with or
without the indicated divalent cation (at 0.5 mM; P+Mg, P+Mn, P+Mg+Mn) and the compounds
DPBA (1) (P+Mg+Mn+DPBA) and L-742,001 (2) (P+Mg+Mn+L-742,001) (at 450 mM, ligand:
protein ratio = 6) were measured in a thermofluorescence experiment. (b) Polyacrylamide/8 M urea
gels of inhibition of endonuclease activity by DPBA (1) and L-742,001 (2). Increasing
concentrations of molecules (1) and (2) were incubated with 20 mM protein and 1 mM single-
stranded RNA. The reaction products were analyzed in 20% polyacrylamide/8 M urea gels. The
lane labelled NC lacked protein in the reaction mixture, while the lane labelled EDTA contained all
reagents plus 5 mM EDTA.
Table 2
Determination of the dissociation constants of ENDO proteins (WT and
D118A and D88A mutants) with DPBA (1) and L-742,001 (2) in the
presence or absence of ions by microscale thermophoresis (MST).
The concentration of labelled protein was kept constant at 100 nM, while the
concentration of the compound was varied from 500 mM to 15 nM to yield 16
serial concentrations. ND, not detectable.
Kd (mM)
WT D118A D88A
Compounds Ion No ion Ion No ion Ion No ion
DPBA (1) 5.38  2.06 ND 18.76  3.88 ND ND ND
L-742,001 (2) 0.51  0.11 ND 0.89  0.06 ND ND ND
thermophoresis to determine the affinity of ENDO-WT and
the ENDO-D88A and ENDO-D118A mutants for DPBA (1)
and L-742,001 (2) in the presence of divalent metal ions (Mg2+
and Mn2+). MST detects changes in the hydration shell of
biomolecules and measures their interactions under close-to-
native conditions. Any change in the hydration shell of
proteins owing to changes in their structure affects the ther-
mophoretic movement, which is used to determine binding
affinities with high accuracy and sensitivity. The results
summarized in Table 2 show that the affinities of ENDO-WT
and ENDO-D118A for DPBA (1) are in the same (micro-
molar) range. However, in the case of L-742,001 (2) the Kd
values for ENDO-WT and ENDO-D118A were about tenfold
and 20-fold lower than that for DPBA (1), respectively. This
suggests that both ENDO-WT and ENDO-D118A display a
higher affinity for L-742,001 (2) than for DPBA (1).
Interestingly, for both compounds no significant affinity was
recorded either for ENDO-WT without metal ions in the
experimental buffer or for ENDO-D88A. This result corro-
borates the idea that the binding of the DKAs (1) and (2)
takes place via the chelation of divalent cations and that
Asp88 is key in this interaction.
We further validated the results obtained with DPBA (1)
using isothermal titration calorimetry (ITC) as an orthogonal
assay. The Kd of DPBA (1) for ENDO-WT and the two
mutants ENDO-D118A and ENDO-D88A were determined
and the data were of the same order as those determined by
MST (Supplementary Fig. S2). ENDO-WT and ENDO-
D118A displayed affinities in the low-micromolar range, while
no interaction was detected for ENDO-D88A, confirming the
earlier results.
3.2. ENDO-WT and ENDO-D118A holoenzyme structures
In the original study of LCMV ENDO (Morin et al., 2010),
the crystallization conditions did not allow the formation of
complexes with cofactors (ionic or otherwise). This was in part
owing to the organization of the molecules in the crystal
asymmetric unit, with one symmetric molecule occupying the
catalytic site. Therefore, for this structural study to be
successful it was critical to search for new crystallization
conditions that would allow the molecules to form ionic
complexes. The present ENDO-WT structure clearly shows
the two Mg2+ ions directly coordinated by the catalytic Asp88
and, through a network of water molecules, by Glu101 and
Lys114 (Supplementary Fig. S3a). From our observation of 100
crystals during the screening and analysis of work performed
on the Lassa virus endonuclease domain, this coordination
event seems to be rare. Indeed, in the structure of the Lassa
virus endonuclease domain reported by Wallat et al. (2014)
similar residues are involved, with a very dense network of
water molecules stabilizing the ions. On the other hand, if we
compare these results with the structure of the Lassa virus
endonuclease domain reported by Reguera et al. (2016), we
can see that the coordination of the two Mn2+ ions involved
the corresponding residues Asp89, Glu102 and Lys115, a
residue from the asymmetric unit (Glu3) and no waters.
Together, these data indicate that the affinity of the Arena-
viridae endonuclease for its catalytic ions is low and that the
metal-ion binding at the catalytic site is the result of a random
event in the absence of an RNA substrate.
In the ENDO-WT structure, the water molecules mimic the
positions of the nonbridged O atoms of the RNA phospho-
diester backbone involved in binding to the ions. This obser-
vation reminded us of previous comments on ribonuclease III,
for which the substrate is proposed to bind to the enzyme
independently and prior to the catalytic ions (Nicholson,
2014). Likewise, this is also the case for the Arenaviridae
exonuclease mechanism, in which the RNA contributes to the
formation of the binding site of the catalytic ion (Jiang et al.,
2013).
Therefore, we propose that in the case of the LCMV
endonuclease domain the RNA substrate is a necessary
contributor to the formation of a transitioning ion-binding/
catalytic site that allows a two-metal-ion catalytic mechanism
(TMIC).
In this study, we decided to assess the impact of a key
residue within the catalytic site (Morin et al., 2010) but a priori
not involved in the mechanism. For this, we mutated a
conserved aspartate to alanine (D118A). From a structural
point of view, we confirmed by crystallography that the
mutation has no effect on the overall LCMV endonuclease
structure (Supplementary Fig. S3b), as preliminarily shown by
the study of the thermal stability of ENDO-D118A by DSF.
3.3. DPBA–ENDO-WT complex
To understand the molecular interactions between DPBA
(1) and ENDO-WT, we solved the structure of their complex.
The DPBA–ENDO-WT complex structure was determined at
1.88 A˚ resolution in space group P41. DPBA (1) binds directly
to the two Mg2+ ions in the active site, as clearly shown by the
2Fo  Fc OMIT map (Figs. 3a, 3b and 3c). However, this
binding mode is rather unusual compared with the binding
configuration observed for DPBA (1) bound to the active sites
of Orthobunyavirus endonuclease and the influenza PA Nter
(Reguera et al., 2010; Kowalinski et al., 2012; DuBois et al.,
2012). Indeed, DPBA (1) binds the first ion through the
carboxylic group and the enolizable -ketone and the second
ion through both the - and -ketones. In the DPBA–ENDO-
WT structure the three adjacent and coplanar O atoms of the
DKA motif of DPBA (1) bind the two metal ions as follows:
Mg1 is coordinated by the carboxylic group and the enolizable
-ketone, whereas Mg2 is coordinated by the carboxyl group
only (Figs. 3a and 3b and Supplementary Fig. S4a). The
-ketone is flipped by about 180 and forms hydrogen bonds
to two water molecules that mediate interaction with Ser46
and Glu50. The phenyl group of DPBA (1) makes no direct
interactions with the residues in the active site.
This difference in binding mode might be owing to the
enlarged nature of the active site of the LCMV ENDO versus
Orthobunyavirus or influenza virus endonucleases, allowing
the compound to adopt alternative conformations.
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3.4. L-742,001–ENDO-WT complex
The L-742,001–ENDO-WT complex was determined in the
same space group as the DPBA–ENDO-WT complex, P41, at
1.97 A˚ resolution. In contrast to DPBA (1), L-742,001 (2)
adopts a conformation that is identical to that reported for
influenza PA Nter (Kowalinski et al., 2012; DuBois et al., 2012).
The two metal ions are chelated by the three coplanar O atoms
of L-742,001 (2) as indicated by the 2Fo  Fc OMIT map
(Figs. 3d, 3e and 3f, and Supplementary Fig. S4b). One of the
Mn2+ ions is coordinated by Asp88 and Glu50 as well as Asp65
and Lys121 via bridging water molecules and by two O atoms
of the ligand. The second metal ion is coordinated by Cys102,
Asp88, two water molecules and two O atoms of the ligand,
leading to an octahedral geometry for both ions. The O atom
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Figure 3
Crystal structures of the ENDO protein in complex with DPBA (1) and L-742,001 (2). LCMV endonuclease structures complexed with (1) (a, b, c) or (2)
(d, e, f ) are shown. Structures are represented as ribbons with helices in green and strands in gold, while the compound is represented as sticks. Mg2+ and
Mn2+ ions are represented as light green and purple spheres, respectively. (b) and (e) show enlargements of the catalytic site showing the strong
coordination of waters, ions and catalytic residues of the molecule. (c) and ( f ) show a 2Fo  Fc OMIT map corresponding to the compound (1).
of the ligand also makes a hydrogen bond to Lys114, which is
an important catalytic residue. The chlorobenzyl and benzyl-
piperidine groups are oriented in opposite directions
perpendicular to the dioxobutanoic acid. The chlorobenzyl
group enters into a pocket comprising Arg47, Ser46, Lys43
and Glu50. The piperidine moiety, on the other hand, is poorly
defined owing to weak electron density compared with the rest
of the molecule. This suggests that some rotational flexibility
exists owing to weak interactions between this part of the
molecule and residues in the flexible region (residues 83–85)
connecting the fourth -helix to the first -strand of the
protein. Moreover, we observed an alternative conformation
for the side chain of Asp88, suggesting that the presence of the
compound removing the ion was sufficient to alter the ‘resting’
position of the side chain.
The overall three-structure comparison (holo structure
and two ligand-complexed structures) raises an interesting
observation concerning the way that ENDO coordinates the
ions depending on the active-site environment. Indeed, in the
holo structure the ions are coordinated by three residues,
Asp88, Glu101 and Lys114, and in the DPBA-complexed
structure the ions are also coordinated by three residues,
Asp88, Glu101 and Asp118 (via a water molecule). On the
other hand, in the L-742,001-complexed structure the ions are
coordinated by Glu50, Asp88 and Leu121. The obvious
difference between the two ligands lies in the fact that DPBA
(1) makes no direct interaction with the enzyme, while
L-742,001 (2) does interact through its chlorobenzyl group.
This observation shows that any perturbation in the active site,
such as a ligand, can trigger ion mobility. Figuratively, the ions
bounce like a pinball in the active site to establish a dynamic
new coordination.
3.5. Evaluation of DPBA (1) and L-742,001 (2) in an in vitro
LCMV endonuclease-activity assay
Having characterized the interactions between the two
ligands and ENDO-WT, we proceeded to test the efficacy of
compounds DPBA (1) and L-742,001 (2) in inhibiting the
LCMV endonuclease activity in an in vitro endonuclease assay.
A single-stranded 50-radio-labelled RNA was incubated with
ENDO-WT at a range of compound concentrations. Cleavage
was analysed on a denaturing polyacrylamide gel and visua-
lized on a phosphoimager (Fig. 2b). As expected, DPBA (1)
and L-742,001 (2) display inhibition of LCMV endonuclease
activity; however, both compounds exhibit weak activity in the
submillimolar range. DPBA (1) is slightly more active than
L-742,001 (2), as its efficacy appears from 250 mM, whereas
that of L-742,001 (2) only appears from 1 mM. DPBA (1) and
L-742,001(2) are both relatively fair binders but very weak
inhibitors of ENDO. However, both were described to be
potent inhibitors of Orthobunyavirus and Orthomyxovirus
endonuclease domains at micromolar and submicromolar
levels. Their potency appeared to be relative to their mode of
binding, which involves both ion
chelation and hydrophobic or
electrostatic interactions with
some amino acids in the vicinity
of the active site (Reguera et al.,
2010; Kowalinski et al., 2012;
DuBois et al., 2012). ENDO
accommodates DPBA (1) and
L-742,001 (2); however, the
binding mode is only driven and
is predominately mediated by
metal chelation. Indeed, if the
ions are removed then the
binding is completely lost (Fig. 2).
The lack of polar interactions
between the compound and the
amino acids of the active site
leads to residual flexibility and
suboptimal efficacy and makes
them ligands but weak inhibitors.
Our assumption in the use of
DKAs is that the compound
competes with the RNA for the
ions at the active site, thus
creating a stable complex that
acts as a steric inhibitor. To
design potent inhibitors, a full-
occupancy binding mode should
be obtained. In order to maximize
our chances, we re-explored
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Figure 4
The five motifs (blue) that are conserved across all available sequences of the Arenaviridae endonuclease
domain plotted on the LCMV structure (grey). Conserved motifs are shown in WebLogo representation.
The size of the letter is representative of the frequency with which it observed in the alignment (with a
probability of 1 being identity). The numbering of the residues refers to the sequence of LCMV. Motifs 1–4
represent the four positions that can be used to anchor a ligand over all Arenaviridae. Residues marked
with a star correspond to key residues involved in the active site or in substrate binding, and their side
chains are highlighted on the structure (orange).
Arenaviridae ENDO sequence–structure conservation to
guide the design of new DKAs that are able to establish
hydrophobic interactions with amino acids of the ENDO
active site.
As its chemical synthesis is more accessible, we chose
DPBA (1) to guide compound optimization, and it will be the
starting point for structure-based drug development.
3.6. Compound optimization and in silico evaluation
From a sequence point of view, Arenaviridae endonuclease
has only five absolutely conserved regions, from which five
motifs can be derived. Four of the five motifs (motifs 1–4) are
located in the vicinity of the catalytic site (Fig. 4). The central
motif 2, PDG, is the endonuclease catalytic signature. Motifs 1,
3 and 4 surround motif 2, forming a hydrophobic slit below the
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Figure 5
(a) Structure of ENDO-WT complexed with Mg ions and the docking grid. The surface is coloured cyan and the conserved motif is coloured orange.
Mg2+ ions are represented as light green spheres. The position of DPBA (1) is shown in the right panel. (b) Selection of the best docking poses of
compounds (3) and (4). (c) Enlargement of the best pose on the cavity surface. (d) Enlargement of the best pose with the residues involved in binding.
These are coloured according to hydrophobicity from cyan (least) to green (most). (e) Polyacrylamide/8 M urea gels of compounds (3) and (4) (50 mM)
incubated with 20 mM protein and 1 mM single-stranded RNA. ( f ) Quantification of endonuclease activity in the presence of DMSO and compounds (1),
(3) and (4).
catalytic site. Motif 1 is the furthest away but contributes
together with the end of motif 2 to the formation of one side of
the slit owing to their hydrophobic nature. Motifs 3 and 4 form
the other side of the slit. They are both hydrophobic but are
punctuated with conserved polar amino acids including
Glu101, Lys114, Asp118 and Lys121. These motifs show that
despite years of evolution and viral diversity across the family,
these residues are invariant and consequently highly impor-
tant for function or fold integrity. Therefore, for compound
optimization these motifs can be used as solid ground to
anchor compatible chemical moieties that would reinforce the
binding and increase the inhibitory effect. In this spirit, and
after gaining insights into how DPBA (1) interacts with
ENDO, we decided to explore the effect of modifications of
the phenyl ring of DPBA (1) in an attempt to improve its
interactions with the amino acids of the active site and
consequently its binding efficacy.
We hypothesized that increasing the aromatic content of the
ligands should reinforce the binding of the corresponding
DKAs by establishing hydrophobic contacts with the residues
of motifs 3 and 4 (Fig. 4).
We designed two new DKAs, compounds (3) and (4),
withbiphenyl and phenanthryl moieties, respectively (Fig. 1b).
The selected aromatic rings reinforce the rigidity and hydro-
phobicity of the compound while increasing its electro-
negativity, potentially allowing broader contacts in pockets.
The biphenyl structure allows a larger degree of freedom
compared with the phenanthryl structure, allowing the second
ring to rotate. Docking simulations confirmed our hypothesis,
showing that increasing the number and type of aromatic
components within the ligand [molecules (3) and (4)] provides
a second ‘anchorage’ into the targeted conserved area of the
catalytic pocket (Figs. 5a, 5b and 5c). The poses of the mole-
cules have a binding energy (E) ranging between 7.2 and
5.5 kcal mol1. This interaction can be described as follows:
(i) the DKA moiety interacts with the first metal ion through
the carboxylic group and the enolizable -ketone and the
second metal ion through both the - and -ketones, and (ii)
the aromatic rings of compounds (3) and (4) generate
hydrophobic interactions of the conserved region of motifs 3
and 4 with residues Phe103, Val104, Lys114 and Tyr146, and of
motifs 1, 3 and 4 with residues Ile49, Glu50, Cys102, Phe103,
Val104, Arg105 and Lys114, respectively (Fig. 5d and
Supplementary Fig. S5).
With this perspective, we synthesized two new DKA
compounds (3) and (4). These compounds were first evaluated
for their affinity for ENDO-WT by MST; DKAs (3) and (4)
displayed Kd values of 0.05  0.02 and 0.25  0.07 mM,
respectively. Both new DKAs showed a tenfold to 100-fold
better affinity compared with DPBA (1), indicating that the
modifications provide additional interactions with ENDO-WT
leading to better binding. We also tested the inhibition of
DKAs (3) and (4) using our in vitro endonuclease-activity
assay (Figs. 5e and 5f). We observed that the intensity of the
undigested RNA in the presence of the DKAs (3) and (4)
remains stronger compared with DPBA (1) (Fig. 5e). Quan-
tification of the intensity of the bands reflects a diminution of
enzyme activity in the presence of the new molecules (3) and
(4). This is an indication that compound modifications
increasing hydrophobic interactions lead to a gain in potency
(conservatively estimated at about 35%). These findings are a
proof of concept that the design of optimized inhibitors,
despite being challenging, is possible when proper structural
information is available.
4. Conclusions
We report four crystallographic structures of the LCMV
endonuclease domain: a complex with two divalent ions
(Mg2+), the D118A mutant and the first two structures of
complexes with ligands – the DKAs DPBA (1) and L-742,001
(2). These structures provide the first detailed structural
information on a specific ligand bound to an arenavirus
endonuclease. Our data show that the presence of ions in the
holo structure is in fact a rare event. The structures show that
the metal-ion binding depends on the number of water
molecules that are able to create a mesh of interaction around
the ions. This suggests that the catalytic ions responsible for
the two-metal-ion catalysis reaction are most likely brought in
by the RNA substrate itself. This study shows that Asp88 is the
critical residue that mediates metal-ion binding. Moreover,
based on an extensive sequence analysis of all Arenaviridae
endonuclease domains, we have identified four motifs that can
be used as anchors for the specificity of optimized compounds
targeting this domain. Our preliminary results, based on two
new optimized DKAs, suggest that aromatic ring modifica-
tions improve binding and mostly anti-ENDO activity. In spite
of the challenge of an open active site, this study is a proof of
concept that knowledge of ligand-bound structures can guide
the design of optimized inhibitors against the LCMV endo-
nuclease domain.
APPENDIX A
Chemistry
All reagents and anhydrous solvents were purchased from
Aldrich and were used without further drying. All reactions
involving air-sensitive or moisture-sensitive compounds were
performed under an argon atmosphere using oven-dried
glassware and syringes. NMR spectra were determined in
DMSO-d6 on a Jeol spectrometer (400 MHz). Chemical shifts
were expressed in p.p.m. and coupling constants (J) are given
in Hertz (s, singlet; d, doublet; m, multiplet). HPLC/MS
spectra were recorded on a Thermo Fisher Accela 600
(detection 260 nm) with an Hypersil-Gold C18 (2.5 mm, 2.1 
50 mm) column and a Finnigan Surveyor MSQ (MS) under
electrospray ionization (ESI) with positive and negative
ionization-mode detection. Compounds were eluted with a
gradient of a solution of 5–100% 0.01% formic acid in aceto-
nitrile solution with a 500 ml min1 flow rate.
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A1. General procedure for the preparation of compounds (3)
and (4)
Sodium (20 mmol) was added slowly to cold methanol in an
ice–water bath to give a 2 M solution of sodium methoxide.
The appropriate aryl methyl ketone (5 mmol) and dimethyl
oxalate (10 mmol) were dissolved in dry THF/DME [1:1(v:v)]
and the solution was added dropwise to the freshly prepared
sodium methoxide. The mixture was stirred at room
temperature for 8 h. The resulting solid was filtered off,
washed with cold methanol and diethyl ether and dried. The
sodium ketoenolate ester obtained was dissolved in water and
stirred at room temperature for 1 h. The solution was then
acidified to pH 3–4 by adding 1 N HCl and kept at 4C for 2 h.
The precipitate was filtered off, washed with cold water and
dried. The ketoenol ester obtained was dissolved in THF/
MeOH [1:1(v:v)] and a solution of 2 N NaOH was added
dropwise. The resulting clear solution was stirred at room
temperature for 1 h. The mixture was acidified to pH 2 by
adding 1 N HCl and the precipitate formed was filtered off,
washed with cold water and dried under vacuum. The crude
material obtained was purified by crystallizing it from diethyl
ether, which yielded the desired aryl diketo acids (3) and (4).
A2. 2-Hydroxy-4-(biphenyl-4-yl)-4-oxobut-2-enoic acid (3)
This was obtained as a yellow solid (212 mg, 27% global
yield) using 4-acetylbiphenyl as the starting material. Tr-
HPLC/MS, 3.87 min. LC-MS (ESI), 266.97 [M–H]; HRMS
ESI calculated for C16H12O4 [M–H]
, 267.0663; found
267.0663. 1H NMR (400 MHz, DMSO-d6)  (p.p.m.): 8.16 (d,
2H, J = 8.1 Hz), 7.88 (d, 2H, J = 8.1 Hz), 7.77 (d, 2H, J =
7.8 Hz), 7.54–7.50 (m, 2H), 7.47–7.38 (m, 1H), 7.15 (s, 1H), 4.60
(s, 2H, methylenic proton of the diketo tautomer, ketoenol/
diketo ratio = 0.1). 13C NMR (100 MHz, DMSO-d6)  (p.p.m.):
189.73, 170.28, 163.16, 145.33, 138.61, 133.39, 129.14, 128.63,
127.24, 127.03, 97.87.
A3. 2-Hydroxy-4-oxo-4-(phenanthren-3-yl)but-2-enoic acid (4)
This was obtained as a yellow solid (185 mg, 23% global
yield) using 3-acetylphenanthrene as the starting material. Tr-
HPLC/MS, 4.10 min. LC-MS (ESI), 290.94 [M–H]; HRMS
ESI calculated for C18H12O4 [M–H]
, 291.0663; found,
291.0664. 1H NMR (400 MHz, DMSO-d6)  (p.p.m.): 9.37 (s,
1H), 9.01 (s, 1H), 8.16–7.90 (m, 5H), 7.76–7.70 (m, 2H), 7.00 (s,
1H), 4.74 (s, 2H, methylenic proton of the diketo tautomer,
ketoenol/diketo ratio = 0.15). 13C NMR (100 MHz, DMSO-d6)
 (p.p.m.): 187.61, 174.57, 164.17, 134.01, 131.79, 131.79, 129.97,
129.37, 129.04, 128.72, 127.46, 127.37, 126.32, 124.89, 123.28,
122.52, 99.13.
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